Available Clinical Trials

In 2006, Dr. Elizabeth Tan-Chiu founded Florida Cancer Research Institute. FCRI's staff and state-of-the-art facility offer FDA approved clinical research trials giving its patients alternatives other than generic therapies usually offered by other general oncologists.

We encourage our patients and physicians to join our network and help make vital contributions to the development of new and better therapies for the treatment of cancer.


Disease

Protocol Title

Metastatic Breast B3271002 - Pfizer
A phase 3 randomized, double-blind study of PF-05280014 plus paclitaxel versus trastuzumab plus paclitaxel for the first-line treatment of patients with HER2-positive metastatic breast cancer
 
Metastatic Breast CP-MGAH22-02
A single arm, open-label, phase 2 study of MGAH22 (fc optimized chimeric ANTI-HER-2 monoclonal antibody ) in patients with relapsed or refractory advanced breast cancer whose tumor express HER2 at the 2+ level by IHC and lackof evidence of HER2 gene amplification by fish
 
Metastatic Breast E7839-A001-208
A Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer
 
Neoadjuvant Breast GSK 113172
A Double Blind, Randomized (2:1) Placebo-controlled Phase I/II study of Neoadjuvant treatment with WT1-A10 plus ASI5 Antigen-Specific Cancer Immunotherapeutic in combination with Standard Therapy in women with WT1-positive Stage II or Stage III breast cancer (Opening 4/28/2011)
 
Neoadjuvant Breast GSK 113172 - (WTI-AS15-BRS-001)
Study of GSK 2302024A Antigen-Specific Cancer Immunotherapeutic combined with Standard Neoadjuvant Treatment in Patients with Positive WT1-positive Primary Invasive Breast Cancer.
 
Metastatic Breast MONALEESA-2 - Novartis
A Randomized, Double-Blind, Placebo-Controlled Study of LEE011 in Combination with Letrozole for the Treatment of Post-menopausal women with Hormone-receptor-positive, HER2-negative, Advanced Breast Cancer who no received no Prior Therapy.
 
Adjuvant Breast PH3-01 - “PRESENT PROTOCOL” Galena Biopharma
Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment.
 
Metastatic Breast PUMA-NER-1301 - PUMA Biotechnology
The NALA Study Neratinib Against Lapatinib in Advanced Breast Cancer. A Phase III Trial of Neratinib plus Capecitabine Vs. Lapatinib + Capecitabine in Patients with Her-2 Positive Metastatic Breast Cancer who have received two or more prior metastatic regimen.
 
Observational Study TCREG-001-00-V2-1209 - CARIS
A Registry of CARIS target now test results for evaluation of correlation with clinical outcomes for cancer

Disease

Protocol Title

Metastatic Breast 11-PIR-11 - Nektar Therapeutics
The beacon study (breast cancer outcomes with NKTR-102): A phase 3 open-label, randomized, multicenter study of NKTR-102 Versus treatment of physician’s choice (TPC) in patients with Locally recurrent or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine
 
Metastatic Breast B025733 - ROCHE
Theresa Trial, A Phase III Randomized, Multicenter, Two-arm, Open-label Trial to Evaluate the Efficacy of T-DM1 Compared with Treatment of Physician’s Choice in Patients with HER2-positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy (closed for enrollment)
 
Metastatic Breast GDC-4950g - Genentech
A Phase II, double-blind, placebo controlled, randomized study of GDC-0941 or GDC-0980 with fulvestrant versus fulvestrant in advanced or metastatic breast cancer in patients resistant to aromatase inhibitor therapy
 
Observational Study ML28257 SystHers Study - Genentech
An observational cohort study of treatment patterns and outcomes in patients with HER2 positive metastatic breast cancer
 
Neoadjuvant Breast MM-121-02-02-07 - Merrimack
A Randomized, Phase 2 Trial of Preoperative MM-121 with Paclitaxel in HER2-Negative Breast Cancer

Disease

Protocol Title

Metastatic breast 120BC201
Phase 2a, Open-Label, Randomized, Noncomparative Study of BIIB021 in CombinationWith Exemestane in Women with Hormone Receptor-Positive, Advanced MetastaticBreast Cancer Who Have Progressed on a Nonsteroidal Aromatase Inhibitor